BiotechTube
BioLab Holdings

BioLab Holdings

Miami, United States· Est.
biolabholdings.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BioLab Holdings, founded in 2018 and headquartered in Miami, is a private commercial-stage company in the tissue engineering and regenerative medicine sector. It has a portfolio of marketed wound care products, including amniotic membrane allografts and a synthetic antimicrobial matrix, targeting the chronic wound market. The company emphasizes a patient-first philosophy, partners with distributors and providers, and is experiencing team growth to support its commercial and R&D activities.

Wound CareChronic Wounds

Technology Platform

Proprietary processing of human amniotic membrane into single, dual, and triple-layer allografts, and development of synthetic antimicrobial matrices (e.g., Microlyte® SAM™) for tissue regeneration and wound healing.

Opportunities

The large and growing global advanced wound care market, driven by diabetes and aging demographics, presents a significant opportunity.
The launch of their synthetic antimicrobial matrix (Microlyte® SAM™) allows them to compete in a scalable, high-growth product category distinct from donor-dependent biologics.
A partnership-driven commercial model provides capital-efficient market access.

Risk Factors

The company faces intense competition from large, established medtech firms and numerous biologics companies.
It is subject to stringent regulatory oversight for both tissue-based and device products, where compliance failures could be catastrophic.
Market adoption requires changing clinician behavior, which is a slow and expensive process.

Competitive Landscape

BioLab competes in the crowded advanced wound biologics and skin substitute market against leaders like Organogenesis (PuraPly®, Affinity®), MiMedx (Epifix®), and Smith & Nephew, as well as many smaller players. Its new synthetic matrix also competes with products like 3M's Microskin™ and other synthetic scaffolds. Differentiation hinges on product performance, clinical data, pricing, and distributor relationships.

More companies in Regenerative Medicine →More companies in United States →